Results

Total Results: over 10,000 records

Showing results for "drugs".

  1. effectivehealthcare.ahrq.gov/sites/default/files/related_files/episodic-migraine-surveillance-report-1.pdf
    June 01, 2022 - Results from included studies: KQ 2. nonsteroidal anti-inflammatory drugs ............ … Rimegepant 75 mg is more effective for migraine than nonsteroidal anti-inflammatory drugs: post hoc … Biohaven Pharmaceuticals I. … Biohaven Pharmaceuticals I. … CNS Drugs. 2020 Oct;34(10):1015-24. doi: 10.1007/s40263-020- 00753-1. PMID: 32857291.
  2. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/episodic-migraine-surveillance-report-1.pdf
    June 01, 2022 - Results from included studies: KQ 2. nonsteroidal anti-inflammatory drugs ............ … Rimegepant 75 mg is more effective for migraine than nonsteroidal anti-inflammatory drugs: post hoc … Biohaven Pharmaceuticals I. … Biohaven Pharmaceuticals I. … CNS Drugs. 2020 Oct;34(10):1015-24. doi: 10.1007/s40263-020- 00753-1. PMID: 32857291.
  3. effectivehealthcare.ahrq.gov/sites/default/files/searching.ppt
    January 01, 2011 - Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. … Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. … or may be incompletely published elsewhere Good check for publication bias Regulatory Web sites: Drugs … That is because the approval process for new drugs and devices requires submission of data that may not … Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. Sassi F, Archard L, McDaid D. 
  4. effectivehealthcare-admin.ahrq.gov/sites/default/files/searching.ppt
    January 01, 2011 - Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. … Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. … or may be incompletely published elsewhere Good check for publication bias Regulatory Web sites: Drugs … That is because the approval process for new drugs and devices requires submission of data that may not … Ottawa: Canadian Agency for Drugs and Technologies in Health; 2008. Sassi F, Archard L, McDaid D. 
  5. ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety/vol1/Galt.pdf
    April 23, 2004 - Giveaway drugs: good intentions, bad design. Health Affairs, 2004;23(1):213–17. 25.
  6. www.ahrq.gov/sites/default/files/wysiwyg/professionals/quality-patient-safety/patient-safety-resources/resources/advances-in-patient-safety/vol1/Galt.pdf
    April 23, 2004 - Giveaway drugs: good intentions, bad design. Health Affairs, 2004;23(1):213–17. 25.
  7. meps.ahrq.gov/data_files/publications/st377/stat377.pdf
    July 01, 2012 - Statistical Brief #377: Trends in Use and Expenditures for Depression among U.S. Adults Age 18 and Older, Civilian Noninstitutionalized Population, 1999 and 2009 STATISTICAL BRIEF #377 July 2012 Trends in Use and Expenditures for Depression among U.S. Adults Age 18 and Older, Civilian Noninstitutionalized Populatio…
  8. www.cahps.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
    January 01, 2009 - and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
  9. www.qualitymeasures.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
    January 01, 2009 - and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
  10. www.innovations.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
    January 01, 2009 - and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
  11. www.healthcare411.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
    January 01, 2009 - and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
  12. www.monahrq.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
    January 01, 2009 - and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
  13. www.talkingquality.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
    January 01, 2009 - and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
  14. ce.effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
    January 01, 2009 - and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
  15. www.ahrq.gov/sites/default/files/wysiwyg/policymakers/chipra/factsheets/fullreports/chipra-89-adhd-behavior-section-5-attach-1.pdf
    January 01, 2009 - and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs … Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
  16. www.ahrq.gov/news/newsletters/e-newsletter/625.html
    July 01, 2018 - Hispanics, and people living in the South or without health insurance were less likely to take the drugs
  17. www.ahrq.gov/news/newsletters/e-newsletter/624.html
    July 01, 2018 - Drugs Aging 2017 Mar;34(3):191-201. Access the abstract on PubMed®.
  18. srdr.ahrq.gov/projects/1565/studies/189585
    January 01, 2017 - Patients with a regular alcohol intake and/or use of psychoactive drugs
  19. effectivehealthcare.ahrq.gov/get-involved/nominated-topics/for-patients-including-both-children-and-adult-subgroup-comparisons-with-type-1-diabetes-what-is-the-comparitive-differences-in-hba1c-levels-when-comparing-various-treatment-options-including-multiple-daily-injections-insulin
    July 19, 2009 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to
  20. effectivehealthcare.ahrq.gov/get-involved/nominated-topics/what-is-the-effectiveness-of-interventions-designed-to-support-children-in-transition-from-pediatric-care-to-adult-care-with-special-health-care-needs-ineffective-transition-planning-can-have-significant-negative-consequences
    January 07, 2013 - yes If yes, explain the specific technologies, devices, drugs, or interventions you would like to